Department of Clinical Immunology and Allergy, Royal Adelaide Hospital, Adelaide South Australia.
J Asthma Allergy. 2008 Nov 30;1:49-54. doi: 10.2147/jaa.s3082.
Ciclesonide is a novel corticosteroid which is optimized for topical use. It is a pro-drug which is activated locally in the airway mucosa, lipid-conjugated for local retention, and has very high protein binding in circulation leading to low systemic bioavailability. These characteristics should lead to highly selective activity with reduced local and systemic side effects. It has been established as an inhaled medication for asthma and has also been shown in double-blind trials to be efficacious for the treatment of seasonal and perennial allergic rhinitis. However no data have yet demonstrated superiority over existing nasal topical corticosteroids, either in terms of efficacy or adverse effects, and trials have not yet clearly shown efficacy in rhinitis in children. Therefore the place of ciclesonide in the treatment of allergic rhinitis relative to other existing products remains unclear.
环索奈德是一种新型皮质类固醇，专门优化用于局部应用。它是一种前药，在气道黏膜中局部激活，与脂质结合以局部保留，并在循环中具有非常高的蛋白结合，导致全身生物利用度低。这些特性应该导致高度选择性的活性，减少局部和全身副作用。它已被确立为一种用于哮喘的吸入药物，并且在双盲试验中也已显示出对季节性和常年性过敏性鼻炎的治疗有效。然而，尚无数据表明它在疗效或不良反应方面优于现有的鼻用皮质类固醇，并且试验尚未清楚地显示其在儿童鼻炎中的疗效。因此，环索奈德在治疗过敏性鼻炎方面相对于其他现有产品的地位仍不清楚。
